

## Session 2

Ayesha: If alcohol's main effect is on neurotransmitters of GABA and Glutamate, how does it trigger dopaminergic reward pathway?

Leslie Hayes: Do we know why rates of AUD are increasing so dramatically?

Donald Foster: I am interested in what they find when they study changes during the pandemic.

- Adam Lake: Also wondering what we could learn from countries where they saw a decrease in alcohol use

Adam Lake: do these sex/gender differences continue in postmenopausal women or in transgender people on hormone therapy? Do we know if this is genetics or hormonal?

- Leslie Hayes: "There was an interesting commentary on this in ASAM's journal last year. . Lowik et al. Where is the Science? A Critical Interrogation of How Sex and Gender are Used to Inform Low-Risk Alcohol Use Guidelines. J. Addict Med Vol 14, No. 5, Sept/Oct 2020"

Basil Spyropoulos: Due to individual variability, isn't CDT more useful with an initial baseline result or in ongoing monitoring?

Sunil Khushalani: How to best use CDT in practice?

Homaira ahad- amiri: What is the criteria for referring patient for treatment of addiction after SBIRT positive.

Adam Lake: What should we expect to know about the OPRM1? That it doesn't work or that it might work?

Bezalel Dantz, MD: if patient has no response or partial response to naltrexone at 50 mg, is their utility in increasing the dose to 100 mg per day?

Ayesha: how often LFTs should be monitored when pt is on naltrexone ?

- Adam Lake: I've always been confused by this recommendation, as I see my GI colleagues using this frequently in cirrhosis for the treatment of cholestatic pruritus

David Roll: What level of LFT abnormality, or what change in LFTs during therapy, would lead you to NOT prescribe or stop prescribing?

Bruce Burns: Where is Clonidine in detox? and/or the benzo sparing theory of detox...